SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

CRIS

Curis, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4d 11h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Cash runway extends only into Q1 2027, requiring additional financing within months. Delisting risk adds urgency. Initial TakeAim CLL data in December 2026 is the next binary catalyst but early-stage and unlikely to change the cash trajectory.

DirectionBearish
Confidencehigh
Horizonweeks

emavusertib

◆ Mixed Named in this press release
Impact
Phase
Phase 2 (registrational-intent in PCNSL)
Time to market
Uncertain; the registrational PCNSL study is still enrolling with full enrollment targeted within 12-18 months from March 2026. If data are positive and an NDA follows, potential approval would be at least 2-3 years out, assuming sufficient capital to complete the trials.
Next catalyst
None dated

What to watchThe next major catalyst is a topline data readout from the registrational TakeAim Lymphoma study in PCNSL, which management targeted to fully enroll within 12-18 months from March 2026 (so late 2027 at the earliest). No specific readout date has been announced. In the near term, watch for the shareholder vote on the proposed reverse stock split, which the company needs to maintain Nasdaq listing, and for any further financing rounds given the cash burn (Q3 2026 net loss of $8.12M).

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$0.4450
T+0 close · Nov 12, 2026 · via day close
Latest settled
−2.07%
T+1 · $0.4358
Vs SPY
−0.16%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $0.4450entry
  2. T+1 · 20h ago −2.07%α −0.16% · $0.4358
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Curis reported Q3 2026 net loss of $8.1M ($1.94 per share) with zero revenue after selling Erivedge royalties in Q4 2025. The company has $5.0M cash plus $7.5M from an October private placement, funding operations only into Q1 2027, and faces Nasdaq delisting risk. Clinical progress in emavusertib studies is early-stage with no near-term revenue catalyst.

Key Financial Metrics

EPS
−$1.94
Revenue
$0.00
est $0.00 · -100.0% YoY

Key Facts

  • Q3 2026 net loss $8.1M ($1.94 per share) vs $7.7M ($9.86) in Q3 2025
  • Zero revenue in Q3 2026 after Erivedge royalty sale in Q4 2025
  • Cash and equivalents $5.0M as of Sep 30, 2026; plus $7.5M from Oct 2026 private placement
  • Cash runway only into Q1 2027
  • Nasdaq delisting determination received Nov 2, 2026; hearing requested but no assurance
  • 12 patients enrolled in TakeAim CLL study; initial data expected Dec 2026
  • R&D expenses $5.6M in Q3 2026 vs $6.4M in Q3 2025
  • 4.1M shares outstanding as of Sep 30, 2026

Financial Impact

Net loss $8.1M in Q3 2026; cash burn rate ~$2.7M/month; cash runway into Q1 2027 only

revenuenet losscashdilution

Risk Factors

  • Nasdaq delisting likely given reverse split already used and discretionary panel monitor
  • Cash runway only into Q1 2027; substantial additional capital needed
  • Zero revenue; no near-term commercialization prospects
  • Early-stage clinical data may not support regulatory approval

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-prn-302938385

Track record

18 reports on CRIS

Performance horizon

6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +82.45% at T+60 after the May 22, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $0.4200 Now $0.4400 +4.76% settles Nov 17
  2. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $0.6000 Now $0.4400 −26.67% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.5010 Now $0.4400 −12.18% settles Nov 17
  4. Nov 13, 20263d ago S-3 Bearish 7/10 Entry $0.6000 Now $0.4400 +26.67% settles Nov 17
  5. Nov 13, 20263d ago 8-K Neutral 4/10 Entry $0.4450 Now $0.4400 −1.12% settles Nov 17
  6. Nov 12, 20264d ago Press Release Bearish 6/10 Viewing Entry $0.4450 to $0.4358 Now $0.4400 +1.12% ▲ +2.07% +0.16% vs SPY
  7. Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $0.6530 to $0.5915 Now $0.4400 −32.62% ▼ −9.42% −10.74% vs SPY
  8. Nov 6, 202610d ago 8-K Bearish 7/10 Entry $0.6976 to $0.6530 Now $0.4400 +36.93% ▲ +6.39% +6.03% vs SPY
  9. Nov 2, 202614d ago DEF 14A Neutral 4/10 Entry $0.6610 to $0.7139 Now $0.4400 −33.43% ▲ +8.00% +7.70% vs SPY
  10. Oct 19, 202628d ago 8-K Bearish 6/10 Entry $0.3996 to $0.3920 Now $0.4400 −10.11% ▲ +1.90% +2.43% vs SPY
Showing 10 of 18

US Market Status

Market Closed · Opens in 6h 18m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026